Open Access“High Tumor Burden” in Metastatic Non-Small Cell Lung Cancer: Defining the Concept
Author(s) -
O. Higuera Gómez,
A. Moreno Paul,
A.L. Ortega Granados,
Silverio Ros Martínez,
Diego Pérez Parente,
P. Ruiz Gracia,
Lucía Sáenz Cuervo-Arango,
Laia Vilà
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s302928
Subject(s) - medicine , lactate dehydrogenase , lung cancer , cancer , oncology , clinical practice , lung , metastasis , family medicine , biochemistry , chemistry , enzyme
Identifying patient characteristics that define a worse disease prognosis or "high tumor burden" (HTB) status is essential for clinical decision-making and treatment selection in metastatic non-small cell lung cancer (mNSCLC). We aimed to define this concept based on the experience of oncologists in clinical practice.